Fabrice André1, Sara Hurvitz2, Angelica Fasolo2, Ling-Ming Tseng2, Guy Jerusalem2, Sharon Wilks2, Ruth O'Regan2, Claudine Isaacs2, Masakazu Toi2, Howard Burris2, Wei He2, Douglas Robinson2, Markus Riester2, Tetiana Taran2, David Chen2, Dennis Slamon2. 1. Fabrice André, Institut Gustav Roussy, INSERM Unit U981, Université Paris Sud, Villejuif, France; Sara Hurvitz and Dennis Slamon, University of California, Los Angeles, Los Angeles, CA; Angelica Fasolo, San Raffaele Scientific Institute, Milan, Italy; Ling-Ming Tseng, National Yang Ming University, Taipei, Taiwan; Guy Jerusalem, University of Liège, Liege, Belgium; Sharon Wilks, Cancer Care Center of South Texas, San Antonio, TX; Ruth O'Regan, University of Wisconsin Carbone Cancer Center, Madison, WI; Claudine Isaacs, Georgetown University, Washington DC; Masakazu Toi, Kyoto University, Sakyo-ku, Kyoto, Japan; Howard Burris, Sarah Cannon Research Institute, Nashville, TN; Wei He, Douglas Robinson, and Markus Riester, Novartis Institutes for BioMedical Research, Cambridge, MA; and Tetiana Taran and David Chen, Novartis Pharmaceuticals Corporation, East Hanover, NJ. Fabrice.ANDRE@gustaveroussy.fr. 2. Fabrice André, Institut Gustav Roussy, INSERM Unit U981, Université Paris Sud, Villejuif, France; Sara Hurvitz and Dennis Slamon, University of California, Los Angeles, Los Angeles, CA; Angelica Fasolo, San Raffaele Scientific Institute, Milan, Italy; Ling-Ming Tseng, National Yang Ming University, Taipei, Taiwan; Guy Jerusalem, University of Liège, Liege, Belgium; Sharon Wilks, Cancer Care Center of South Texas, San Antonio, TX; Ruth O'Regan, University of Wisconsin Carbone Cancer Center, Madison, WI; Claudine Isaacs, Georgetown University, Washington DC; Masakazu Toi, Kyoto University, Sakyo-ku, Kyoto, Japan; Howard Burris, Sarah Cannon Research Institute, Nashville, TN; Wei He, Douglas Robinson, and Markus Riester, Novartis Institutes for BioMedical Research, Cambridge, MA; and Tetiana Taran and David Chen, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Abstract
PURPOSE: Two recent phase III trials, BOLERO-1 and BOLERO-3 (Breast Cancer Trials of Oral Everolimus), evaluated the addition of everolimus to trastuzumab and chemotherapy in human epidermal growth factor receptor 2-overexpressing advanced breast cancer. The current analysis aimed to identify biomarkers to predict the clinical efficacy of everolimus treatment. METHODS: Archival tumor samples from patients in BOLERO-1 and BOLERO-3 were analyzed using next-generation sequencing, immunohistochemistry, and Sanger sequencing. RESULTS: Biomarker data were available for 549 patients. PIK3CA activating mutations and PTEN loss were reported in 30% and 16% of BOLERO-1 samples and in 32% and 12% of BOLERO-3 samples, respectively. PI3K pathway was hyperactive (PIK3CA mutations and/or PTEN loss and/or AKT1 mutation) in 47% of BOLERO-1 and 41% of BOLERO-3 samples. In both studies, differential progression-free survival (PFS) benefits of everolimus were consistently observed in patient subgroups defined by their PI3K pathway status. When analyzing combined data sets of both studies, everolimus was associated with a decreased hazard of progression in patients with PIK3CA mutations (hazard ratio [HR], 0.67; 95% CI, 0.45 to 1.00), PTEN loss (HR, 0.54; 95% CI, 0.31 to 0.96), or hyperactive PI3K pathway (HR, 0.67; 95% CI, 0.48 to 0.93). Patients with wild-type PIK3CA (HR, 1.10; 95% CI, 0.83 to 1.46), normal PTEN (HR, 1.00; 95% CI, 0.80 to 1.26), or normal PI3K pathway activity (HR, 1.19; 95% CI, 0.87 to 1.62) did not derive PFS benefit from everolimus. CONCLUSION: This analysis, although exploratory, suggests that patients with human epidermal growth factor receptor 2-positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive PFS benefit from everolimus.
PURPOSE: Two recent phase III trials, BOLERO-1 and BOLERO-3 (Breast Cancer Trials of Oral Everolimus), evaluated the addition of everolimus to trastuzumab and chemotherapy in humanepidermal growth factor receptor 2-overexpressing advanced breast cancer. The current analysis aimed to identify biomarkers to predict the clinical efficacy of everolimus treatment. METHODS: Archival tumor samples from patients in BOLERO-1 and BOLERO-3 were analyzed using next-generation sequencing, immunohistochemistry, and Sanger sequencing. RESULTS: Biomarker data were available for 549 patients. PIK3CA activating mutations and PTEN loss were reported in 30% and 16% of BOLERO-1 samples and in 32% and 12% of BOLERO-3 samples, respectively. PI3K pathway was hyperactive (PIK3CA mutations and/or PTEN loss and/or AKT1 mutation) in 47% of BOLERO-1 and 41% of BOLERO-3 samples. In both studies, differential progression-free survival (PFS) benefits of everolimus were consistently observed in patient subgroups defined by their PI3K pathway status. When analyzing combined data sets of both studies, everolimus was associated with a decreased hazard of progression in patients with PIK3CA mutations (hazard ratio [HR], 0.67; 95% CI, 0.45 to 1.00), PTEN loss (HR, 0.54; 95% CI, 0.31 to 0.96), or hyperactive PI3K pathway (HR, 0.67; 95% CI, 0.48 to 0.93). Patients with wild-type PIK3CA (HR, 1.10; 95% CI, 0.83 to 1.46), normal PTEN (HR, 1.00; 95% CI, 0.80 to 1.26), or normal PI3K pathway activity (HR, 1.19; 95% CI, 0.87 to 1.62) did not derive PFS benefit from everolimus. CONCLUSION: This analysis, although exploratory, suggests that patients with humanepidermal growth factor receptor 2-positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive PFS benefit from everolimus.
Authors: David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham Journal: Cell Date: 2017-08-10 Impact factor: 41.582
Authors: A Jo Chien; Debasish Tripathy; Kathy S Albain; W Fraser Symmans; Hope S Rugo; Michelle E Melisko; Anne M Wallace; Richard Schwab; Teresa Helsten; Andres Forero-Torres; Erica Stringer-Reasor; Erin D Ellis; Henry G Kaplan; Rita Nanda; Nora Jaskowiak; Rashmi Murthy; Constantine Godellas; Judy C Boughey; Anthony D Elias; Barbara B Haley; Kathleen Kemmer; Claudine Isaacs; Amy S Clark; Julie E Lang; Janice Lu; Larissa Korde; Kirsten K Edmiston; Donald W Northfelt; Rebecca K Viscusi; Douglas Yee; Jane Perlmutter; Nola M Hylton; Laura J Van't Veer; Angela DeMichele; Amy Wilson; Garry Peterson; Meredith B Buxton; Melissa Paoloni; Julia Clennell; Scott Berry; Jeffrey B Matthews; Katherine Steeg; Ruby Singhrao; Gillian L Hirst; Ashish Sanil; Christina Yau; Smita M Asare; Donald A Berry; Laura J Esserman Journal: J Clin Oncol Date: 2019-02-07 Impact factor: 44.544
Authors: Maria Mitsogianni; Ioannis P Trontzas; Georgia Gomatou; Stephanie Ioannou; Nikolaos K Syrigos; Elias A Kotteas Journal: Oncol Lett Date: 2021-02-12 Impact factor: 2.967
Authors: Shumei Kato; Nithya Krishnamurthy; Kimberly C Banks; Pradip De; Kirstin Williams; Casey Williams; Brian Leyland-Jones; Scott M Lippman; Richard B Lanman; Razelle Kurzrock Journal: Cancer Res Date: 2017-06-22 Impact factor: 12.701
Authors: Dhivya R Sudhan; Angel Guerrero-Zotano; Helen Won; Paula González Ericsson; Alberto Servetto; Mariela Huerta-Rosario; Dan Ye; Kyung-Min Lee; Luigi Formisano; Yan Guo; Qi Liu; Lisa N Kinch; Monica Red Brewer; Teresa Dugger; James Koch; Michael J Wick; Richard E Cutler; Alshad S Lalani; Richard Bryce; Alan Auerbach; Ariella B Hanker; Carlos L Arteaga Journal: Cancer Cell Date: 2020-01-23 Impact factor: 31.743